VISCHER assists CRISPR Therapeutics in all Swiss law matters regarding a joint venture to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. Bayer will provide a minimum of USD 300 million in R&D investments to the JV over the next five years. In addition, Bayer will acquire a minority stake in CRISPR Therapeutics for USD 35 million in cash.
The team at VISCHER was led by Matthias Staehelin with Angelo Imperiale (both Corporate) and Nadia Tarolli (Tax).